Yifan Tai,Angela Chow,Seoyoung Han,Courtney Coker,Wanchao Ma,Yifan Gu,Valeria Estrada Navarro,Manoj Kandpal,Hanina Hibshoosh,Kevin Kalinsky,Katia Manova-Todorova,Anton Safonov,Elaine M Walsh,Mark Robson,Larry Norton,Richard Baer,Taha Merghoub,Anup K Biswas,Swarnali Acharyya

Abstract:Abstract Acquired resistance to PARP inhibitors (PARPi) remains a treatment challenge for BRCA 1/2-mutant breast cancer that drastically shortens patient survival. Although several resistance mechanisms have been identified, none have been successfully targeted in the clinic. Using new PARPi-resistance models of Brca1 - and Bard1 -mutant breast cancer generated in-vivo, we identified FLT1 (VEGFR1) as a driver of resistance. Unlike the known role of VEGF signaling in angiogenesis, we demonstrate a novel, non-canonical role for FLT1 signaling that protects cancer cells from PARPi in-vivo through a combination of cell-intrinsic and cell-extrinsic pathways. We demonstrate that FLT1 blockade suppresses AKT activation, increases tumor infiltration of CD8 + T cells, and causes dramatic regression of PARPi-resistant breast tumors in a T-cell-dependent manner. Moreover, PARPi-resistant tumor cells can be readily re-sensitized to PARPi by targeting Flt1 either genetically ( Flt1 -suppression) or pharmacologically (axitinib). Importantly, a retrospective series of breast cancer patients treated with PARPi demonstrated shorter progression-free survival in cases with FLT1 activation at pre-treatment. Our study therefore identifies FLT1 as a potential therapeutic target in PARPi-resistant, BRCA1/2 -mutant breast cancer.

FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer